Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

Company Overview

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company headquartered in Tarrytown, New York. Since its founding in 1988 by Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos, the firm has focused on discovering, developing, and commercializing novel medicines for serious medical conditions. Drawing on its integrated research and development model, Regeneron combines genetic insights with proprietary technology platforms to advance therapeutic candidates from early discovery through regulatory approval.

The company’s portfolio includes EYLEA, an anti-VEGF therapy for wet age-related macular degeneration and other eye diseases; Dupixent, an anti-IL-4 receptor alpha antibody approved for atopic dermatitis, asthma and related conditions; and Libtayo, a PD-1 inhibitor indicated for certain skin and lung cancers. In collaboration with Sanofi, Regeneron has also brought forward treatments such as Praluent for hypercholesterolemia and Kevzara for rheumatoid arthritis. During the COVID-19 pandemic, Regeneron developed a monoclonal antibody cocktail, REGEN-COV, which received emergency use authorization for post-exposure prophylaxis and treatment in high-risk patients.

Regeneron’s research engine is built on its VelociSuite technology, which includes VelociGene and VelocImmune platforms designed to accelerate target identification and antibody generation. This approach has enabled the company to build a robust pipeline spanning immuno-oncology, metabolic and ophthalmic disorders, as well as rare diseases. Regeneron continues to invest in translational science to explore new targets and refine personalized medicine strategies.

With a global footprint spanning North America, Europe, Asia and beyond, Regeneron collaborates with academic institutions, government agencies and industry partners. Under the leadership of Dr. Schleifer as CEO and President and Dr. Yancopoulos as President and Chief Scientific Officer, the company remains committed to delivering innovative therapies that address unmet medical needs worldwide.

Key Stats

• Today's Range: $521.00 to $548.03
• 50-Day Range: $483.07 to $614.79
• 52-Week Range: $476.49 to $1,211.20
• Volume: 1.20 million shs
• Average Volume: 903,303 shs
• Market Capitalization: $57.75 billion
• P/E Ratio: 13.62
• Dividend Yield: 0.66%
• Price Target: $813.57
• Consensus Rating: Moderate Buy

Regeneron Pharmaceuticals Stock Analysis - MarketRank™

Regeneron Pharmaceuticals scored higher than 99% of companies evaluated by MarketBeat, and ranked 19th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Regeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 15 buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Regeneron Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.85%

Earnings Growth

Earnings for Regeneron Pharmaceuticals are expected to grow by 5.85% in the coming year, from $35.92 to $38.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Regeneron Pharmaceuticals is 13.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.87.

Price to Earnings Ratio vs. Sector

The P/E ratio of Regeneron Pharmaceuticals is 13.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.22.

Price to Earnings Growth Ratio

Regeneron Pharmaceuticals has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Regeneron Pharmaceuticals has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.95% of the float of Regeneron Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regeneron Pharmaceuticals has recently decreased by 24.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Regeneron Pharmaceuticals has a dividend yield of 0.67%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Regeneron Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Regeneron Pharmaceuticals is 8.96%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 9.26% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 2.3 / 5
• Environmental Score: -2.69

Percentage of Shares Shorted

1.95% of the float of Regeneron Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regeneron Pharmaceuticals has recently decreased by 24.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.81

News Sentiment

Regeneron Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Regeneron Pharmaceuticals this week, compared to 32 articles on an average week.

Search Interest

Only 30 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.

MarketBeat Follows

14 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 56% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.02% of the stock of Regeneron Pharmaceuticals is held by insiders.

Percentage Held by Institutions

83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

REGN Stock Analysis - Frequently Asked Questions

How have REGN shares performed this year?

Regeneron Pharmaceuticals' stock was trading at $712.33 at the beginning of the year. Since then, REGN stock has decreased by 24.9% and is now trading at $534.91.
View the best growth stocks for 2025 here.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its earnings results on Tuesday, April, 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by $0.61. The business's revenue for the quarter was down 3.7% on a year-over-year basis.
Read the conference call transcript.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more.

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' top institutional investors include Harbor Investment Advisory LLC. Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi and N Anthony Coles.
View institutional ownership trends.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 4/29/2025
• Record date for 6/6 Dividend: 5/20/2025
• Ex-Dividend for 6/6 Dividend: 5/20/2025
• Dividend Payable: 6/06/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:REGN
• CIK: 872589
• Web: www.regeneron.com
• Phone: (914) 847-7000
• Fax: 914-347-2113
• Employees: 15,106
• Year Founded: 1988

Price Target and Rating

• Average Stock Price Target: $813.57
• High Stock Price Target: $1,200.00
• Low Stock Price Target: $150.00
• Potential Upside/Downside: +51.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 25 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $39.28
• Trailing P/E Ratio: 13.71
• Forward P/E Ratio: 14.98
• P/E Growth: 1.91
• Net Income: $4.41 billion
• Net Margins: 31.94%
• Pretax Margin: 35.38%
• Return on Equity: 15.27%
• Return on Assets: 11.93%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 4.93
• Quick Ratio: 4.03

Sales & Book Value

• Annual Sales: $14.20 billion
• Price / Sales: 4.09
• Cash Flow: $47.19 per share
• Price / Cash Flow: 11.40
• Book Value: $268.50 per share
• Price / Book: 2.00

Miscellaneous

• Outstanding Shares: 107,960,000
• Free Float: 100,386,000
• Market Cap: $58.07 billion
• Optionable: Optionable
• Beta: 0.31